Overview of Algozone 500 mg

Property	Description
Active Ingredient	Metamizole Sodium (Dipyrone)
Form	Tablet (Oral) and Solution (Parenteral)
Pharmacological Class	Non-opioid Analgesic, Antipyretic, Pyrazolone Derivative
General Use	Pain, Fever, Spasms
Origin	Synthetic

Algozone 500 mg is a proprietary medicinal product whose active ingredient is Metamizole Sodium, an entity also internationally recognized as Dipyrone. This synthetic compound belongs to the pyrazolone derivative chemical group, classifying it as a potent non-opioid analgesic and antipyretic agent. The 500 mg designation refers to the amount of active substance in the common oral tablet form, though the medicine is also formulated for parenteral administration. This substance is established for its application in managing acute pain states.

Composition and Classification: Understanding Metamizole Sodium

The medicine's composition is exclusively centered around the Metamizole Sodium entity, which provides a pharmacological profile distinct from other widely used pain and fever reducers, such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and paracetamol. A key differentiating feature derived from its pharmacological class is the additional spasmolytic property, meaning it can induce the relaxation of smooth muscles in internal organs. Metamizole has an established use for conditions involving pain and high fever. Consequently, the medicine is utilized for addressing both symptomatic discomfort and elevated body temperature. This unique profile distinguishes the Metamizole Sodium formulation from pure analgesics in many global markets.

General Purpose: Analgesia, Antipyresis, and Spasmolysis

Algozone 500 mg provides symptomatic relief by addressing pain relief (analgesia), the reduction of elevated body temperature (antipyresis), and the alleviation of discomfort caused by muscle cramps or spasms (spasmolysis). This combination of three distinct physiological effects enables the product to address compound discomforts where fever, sharp pain, and involuntary muscle contractions may simultaneously contribute to the patient's acute state. Metamizole features a rapid onset of action, making it a choice for managing acute, intense discomfort, such as in cases of renal or biliary colic.

Therapeutic Uses of Algozone 500 mg

What Algozone 500 mg Treats: Main Uses and Benefits

This medicine is used for symptomatic relief across three major therapeutic domains: analgesia (pain relief), antipyresis (fever reduction), and management of pain associated with spasms. The product's application is focused on symptomatic management.

The medication is commonly used to help with symptom clusters that may become intense or disruptive, including post-operative pain, discomfort following acute trauma, intense headaches, and dental pain. The medication is applied in addressing symptoms linked to organ-specific functional stress, such as visceral pain and cramping associated with renal colic or biliary colic. Furthermore, it is applied in addressing high-grade fever when symptoms create noticeable physiological strain.

“The medication helps address groups of symptoms that may appear suddenly and create noticeable physiological strain.”

This comprehensive profile means the medicine supports the patient during difficult episodes by easing the overall symptom load, assists with maintaining functional stability, and may assist with day-to-day comfort during symptomatic periods.

Quick Fact: Support for Acute Pain Associated with Spasms

The medication is relevant for easing acute pain that involves smooth muscle contractions and tension, such as that seen in colic, and is used when symptoms cluster into patterns requiring supportive management.

Eligibility and Restrictions for Use

The eligibility for Algozone 500 mg (Metamizole Sodium) is governed by official regulatory labeling, which establishes both absolute contraindications and specific conditional use requirements.

Category	Official Eligibility Status
Contraindicated Populations	Individuals with a history of agranulocytosis caused by Metamizole or similar agents, or those with existing impaired bone marrow function, must not use this medicine. Use is also prohibited for women in the third trimester of pregnancy and in infants below 3 months or 5 kg of weight.
Age-Group Eligibility	Standard use is documented for adults and adolescents aged 15 years and older. Due to the fixed strength, the 500 mg tablet is not recommended for children younger than 15 years.
Conditional Use	Use during the first six months of pregnancy and while breastfeeding is not recommended and generally should be avoided. Patients with severe impaired liver or kidney function require special caution and a potential dose adjustment, as stated in the regulatory label.

This regulatory framework strictly defines the populations who can safely be treated under labeled conditions, while enforcing non-eligibility for groups identified as high-risk, such as those with haematological issues or women in late pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Algozone 500 mg (Metamizole Sodium) possesses a defined interaction profile based on official regulatory documentation, characterized by both pharmacokinetic and pharmacodynamic constraints.

Official Interaction Statements

Contraindicated Combinations: Co-administration with other Pyrazolone or Pyrazolidine derivatives is officially prohibited due to the serious additive risk of blood dyscrasias. The use is also restricted in patients with impaired bone marrow function.
Pharmacokinetic Interactions: Metamizole is a moderate inducer of CYP3A4, CYP2B6, and CYP2C19, which can lead to a clinically significant reduction in the plasma concentrations of co-administered CYP substrates, including Ciclosporine, Efavirenz, Methadone, Bupropion, and Valproic Acid. Conversely, Metamizole is a weak inhibitor of CYP1A2, which can result in a modest increase in exposure for substrates like Caffeine and Theophylline.
Pharmacodynamic Interference and Reinforcement: Metamizole interferes with the antiplatelet effect of low-dose Acetylsalicylic Acid (ASA). To maintain ASA's intended action, a mandatory timing rule requires ASA to be administered at least 30 minutes before Metamizole. Co-administration with Chlorpromazine carries the officially documented risk of severe hypothermia. The official label also documents a reinforcement of effects with alcohol (ethanol).
Population-Specific Notes: In patients with impaired liver function, the half-life of the active metabolite (4-MAA) is prolonged, a condition which is noted in regulatory documents as potentially heightening the interaction potential with other medicines.

These statements collectively establish the mandated restrictions and monitoring requirements for co-administration as defined by the official regulatory documents.

Mechanism of Action

How Algozone 500 mg Works

Algozone 500 mg acts primarily through the selective, non-competitive inhibition of the enzyme Farnesyl Pyrophosphate Synthase ( FPPS) in the mevalonate pathway. This key biological target prevents the synthesis of crucial isoprenoid lipids, such as farnesyl pyrophosphate ( FPP) and geranylgeranyl pyrophosphate ( GGPP).

The depletion of these lipids prevents the post-translational lipidation (prenylation) of small GTPases (e.g., Ras, Rho, and Rac). This cascade inactivates the GTPases, disrupting their necessary localization to the cell membrane and subsequent intracellular signaling. The resulting effect is a reduction in the bone resorption capacity of osteoclasts through the modulation of their critical function and survival pathways, leading to an overall physiological shift toward reduced bone turnover.

Dosage and Administration Information

Algozone 500 mg (Metamizole Sodium) is used according to established parameters. The medicine is utilized across several distinct administration routes, featuring various pharmaceutical forms.

Administration Route	Commonly Used Form
Oral	500 mg Tablets or Capsules
Parenteral	Solution for Injection (IV and IM)
Rectal	Suppository

Usage is scheduled with a minimum 6 to 8 hour interval between consecutive doses, and the treatment duration is generally kept to the shortest time necessary for symptomatic management. Adult dosing does not exceed the specified maximum daily limits, which are 4,000 mg for oral use and 5,000 mg for parenteral use.

Treatment initiation typically employs the lowest effective single dose. Specific administration constraints govern the parenteral route: Intravenous (IV) administration is required to be performed very slowly as a procedural necessity.

Furthermore, dosing for pediatric patients (age le 14 years) is not fixed; the dose is calculated based on body weight (8 to 16 mg per kg). For older adults or those with existing hepatic or renal impairment, the lowest dose and potentially reduced frequency are utilized.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Algozone 500 mg

Research Evidence for Acute Pain Management

Algozone 500 mg was evaluated in research exploring how outcomes related to physical discomfort change over time, particularly in patients experiencing severe, sudden pain following surgery or trauma. Research in this area primarily relies on short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies monitored changes in patient-reported pain scores and study endpoints included the administration patterns of rescue analgesic medication. Some trials reported different patterns related to the recorded use of concomitant rescue analgesics, such as opioids, in the observed populations. These findings describe patterns observed in the studies but do not represent a guarantee of individual outcomes.

What remains uncertain is the long-term profile of this agent for symptomatic discomfort. The follow-up durations were limited, meaning there is limited information for long-term outcomes or how well this agent was observed in contexts requiring use for many days or weeks.

Research Evidence for Pain Associated with Spasms (Visceral Colic)

Algozone 500 mg was studied for conditions associated with acute or disruptive episodes, such as pain due to renal or biliary colic, where pain is often linked to muscle tension. The research in this area includes RCTs and comparative non-randomized studies often used in acute settings. The research explores the concurrent evaluation of outcomes related to physical discomfort and the symptoms of muscle tension (spasmolysis).

Studies monitored the time elapsed until initial symptomatic change was reported and how pain scores evolved over a few hours. The evidence quality varies across studies for this specific indication. While findings indicate specific patterns related to symptomatic change, the data for preventing recurrence of colic episodes is limited.

Research Evidence for Difficult-to-Treat High Fever (Antipyresis)

The use of Algozone for high fever was evaluated in outcomes related to systemic or functional imbalance when the body’s temperature is significantly elevated and has not responded to other common fever reducers. The evidence base includes regulatory reviews of established clinical use and comparative trials in both adult and pediatric patients. The primary outcome monitored by researchers was the degree and duration of measured temperature change during the observation period. Data for certain groups remain insufficient, particularly in modern, large-scale, head-to-head comparisons across diverse adult populations, meaning certainty remains low for some specific patient subgroups.

What Research Gaps and Uncertainties Remain

Research into Algozone 500 mg explores the evaluation of the agent in managing severe, acute discomfort and fever. However, regulatory summaries and systematic reviews note several key limitations. The main limitation is that the follow-up durations were limited in many of the core trials, meaning long-term effects are not fully established. Also, evidence quality varies across studies, and the data for certain groups remain insufficient. The evidence contributes to understanding group patterns but not individual predictions about a patient’s specific response.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Algozone 500 mg (FAQ)

Q: Can I take Algozone 500 mg with food or on an empty stomach?

According to the official product information for the oral tablet form, Algozone 500 mg can generally be taken either with a meal or on an empty stomach.

Regulatory documents indicate the effectiveness is generally not dependent on co-administration with food.

Q: Does Algozone 500 mg cause drowsiness or fatigue?

The official drug label does not consistently list general drowsiness or fatigue as common side effects of Algozone 500 mg.

However, some regulatory documents have noted that neurological effects, such as dizziness, are a possible undesirable effect. The drug is generally not anticipated to affect concentration.

Q: Are there any interactions with herbal remedies, vitamins, or general supplements?

Official regulatory documents focus on listing known interactions with prescription medicines that affect certain liver enzymes (CYP enzymes).

Most common nutritional supplements and herbal remedies are not specifically addressed as known interacting substances, and their interaction potential is typically not specifically addressed in the official regulatory documents.

Q: Is it safe to drive or operate machinery after taking this drug?

Official drug information indicates that, for most people taking the recommended amount, Algozone 500 mg is not expected to adversely affect the ability to drive or use complex equipment.

However, because dizziness is a possible documented side effect, if an individual experiences such effects, they should exercise caution before engaging in activities that require full concentration.

Q: Does Algozone 500 mg affect the heart or blood pressure?

Yes, official regulatory information notes that hypotensive reactions, meaning a sudden drop in blood pressure, are a potential undesirable effect, particularly when the medicine is administered by injection.

Official documentation notes that caution is advised for patients with pre-existing low blood pressure or severe heart disease.

Q: Is Algozone 500 mg an anti-inflammatory drug?

Metamizole Sodium is primarily classified in regulatory documents as a non-opioid pain reliever and fever reducer, and it also possesses spasmolytic properties (muscle-relaxing effects).

While it may have some minor anti-inflammatory properties, its classification and primary therapeutic use differ from traditional Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Q: How long does Algozone 500 mg stay in the body (half-life and clearance)?

The active component of Algozone 500 mg, known as the MAA metabolite, has a terminal half-life that typically ranges between approximately 2.6 to 3.5 hours.

This half-life describes the general rate at which the substance is cleared from the bloodstream. Official documents note that clearance time is typically slower in patients who have existing liver or kidney impairment.

Q: What are the signs of a serious allergic reaction to Algozone 500 mg?

Official regulatory summaries list life-threatening effects such as anaphylactic shock and agranulocytosis (a severe drop in white blood cells) as rare but serious concerns.

Symptoms of agranulocytosis can include fever, chills, a severe sore throat, or painful sores developing in the mouth or throat. These symptoms are described in the official safety summary.

Q: Can Algozone 500 mg cause headaches as a side effect?

Headaches are not usually listed among the common side effects detailed in the official product information for Algozone 500 mg.

The regulatory documents instead focus on other possible neurological events, such as dizziness, which have been documented as possible side effects.

Q: Is Algozone 500 mg considered a controlled substance?

Algozone 500 mg, which contains Metamizole Sodium, is a non-opioid analgesic and is not classified as a controlled substance.

However, the regulatory status for this medication varies significantly across global jurisdictions, and official documents confirm it has been withdrawn or banned in certain countries due to safety concerns related to agranulocytosis.

Q: Does this drug require specialist prescribing or monitoring?

The official documents do not mandate that only a specialist can prescribe Algozone 500 mg.

However, due to the rare risk of the serious blood disorder agranulocytosis, regulatory summaries advise immediate blood monitoring if a patient develops related symptoms. Medical supervision may be required if any symptoms of a severe reaction are reported.

Q: Does Algozone 500 mg have potential for addiction or dependency?

Metamizole is categorized as a non-opioid drug.

Because its mechanism of action is distinct from narcotic pain medication, official product information does not list the potential for addiction or dependency as a concern.

How should Algozone 500 mg be stored and disposed of?

Official Storage and Disposal Requirements

Algozone 500 mg tablets must be stored according to regulatory conditions to ensure stability and proper shelf-life. The tablets require storage at a temperature not exceeding 25 C and must be kept in their original packaging to protect the product from light.

Requirement	Official Instruction
Temperature	Store below 25 C. Do not refrigerate or freeze.
Packaging	Keep in original container, protected from light.
Safety	Keep out of the sight and reach of children.
Shelf-Life	Do not use after the labeled expiry date.

For disposal, regulatory rules prohibit discarding the medicine in the sewage system or with regular household waste. Unused or expired Algozone 500 mg must be disposed of following local regulations for pharmaceutical waste, often by returning it to a designated collection point like a pharmacy.

Algozone 500 mg